Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.
The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis.
In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton.
The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019.
Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.75 Increased by +13.79% | -0.71 Decreased by -5.63% |
| Aug 1, 24 | -0.70 Increased by +10.26% | -0.74 Increased by +5.41% |
| May 15, 24 | -0.69 Increased by +5.48% | -0.79 Increased by +12.66% |
| Feb 22, 24 | -0.71 Decreased by -33.96% | -0.96 Increased by +26.04% |
| Nov 9, 23 | -0.87 Decreased by -64.15% | -0.81 Decreased by -7.41% |
| Aug 10, 23 | -0.78 Decreased by -20.00% | -0.78 |
| May 11, 23 | -0.73 Decreased by -30.36% | -0.62 Decreased by -17.74% |
| Mar 23, 23 | -0.53 Decreased by -17.78% | -0.67 Increased by +20.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -28.74 M Increased by +12.83% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -26.86 M Increased by +9.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -26.34 M Decreased by -1.81% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.66 M Increased by +N/A% | -27.29 M Decreased by -6.16% | Decreased by -1.65 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -32.97 M Decreased by -102.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -29.60 M Decreased by -24.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -25.87 M Decreased by -39.29% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -25.70 M Decreased by -57.30% | Decreased by N/A% Decreased by N/A% |